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Since the introduction of novel agents (thalidomide, 
lenalidomide, bortezomib) into clinical practice, the 
median overall survival (OS) from the time of diagnosis 
for transplant-eligible patients with multiple myeloma 
(MM) improved greatly from 3–4 years to 7–8 years [1-
3]. On the other hand extramedullary localization of MM 
to central nervous system (CNS-MM) still has a dismal 
prognosis. CNS-MM, i.e. leptomeningeal involvement, 
is rare and accounts for about 1% of the patients with 
MM. Primary parenchymal brain lesions without 
osseous or dural contact without leptomeningeal 
involvement are even rarer [4]. Given the lack of clinical 
series and the peculiar localization within a “sanctuary”, 
the management of IC-MM is a clinical challenge. This 
may result from the nature of the blood-brain barrier 
(BBB) which constitutes a natural protection from 
several drugs that are commonly utilized for the 
treatment of MM.
 
Other three barriers are present at 
interfaces of blood vessels, i.e. the blood-arachnoid 
barrier, the blood-retinal barrier, and the blood-nerve 
barrier. There are diverse treatments for CNS-MM, 
which include systemic chemotherapy (CHT), 
intrathecal therapy, (IT), and radiotherapy (RT), with 
median survivals between 1 and 6 months.
 
Recent 
discoveries on the fundamental molecular mechanisms 
behind MM cell growth and survival have led to the 
introduction of novel classes of pharmacologic agents 
such as the immunomodulatory drugs (IMiDs) and 
proteasome inhibitors (bortezomib). However, the 
activity of new drugs against IC-MM is largely 
unknown. Although bortezomib does not cross the 
BBB, and thalidomide and lenalidomide are reported by 
their activity against intracranial tumors other than MM 
has been described recently, probably because of 
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the manufacturer to have only a minimal crossover, 
disruption of the BBB and increased vascular 
permeability within the tumor [5,25].
 
In fact in one study 
clinical and biological data were retrospectively 
reported regarding patients presenting with an osteo-
dural or primary dural multiple myeloma (OD/D-MM) or 
a central nervous system myelomatosis (CNS-MM). 
New therapies were used in 35/50 patients whereas 
15/50 patients received old chemotherapy treatments. 
Twenty-five out of 50 patients obtained a complete 
remission or a very good partial remission 
(CR+VGPR). Median OS for CNS-MM was 6 months, 
for OD/D-MM 25 months. OS for IC-MM patients 
treated with new agents was 25 months vs. 8 months 
for patients treated with old agents. Improved OS and 
PFS were predicted by: response (CR+VGPR),by 
patients who received SCT vs. CHT. Stem cell 
transplants (SCT) plus novel agents and RT seemed 
the better choice for younger eligible patients. SCT has 
been reported in the past as a treatment capable of 
prolonging survival, even in the era of old agents, 
signifying that dose intensification could be important 
also in this set of patients [10]. Second generation 
IMID’s and proteasome inhibitors hold promise to be 
more effective and to ameloriate responses in CNS-
MM. Pomalidomide (CC-4047) – a novel 
immunomodulatory derivative (IMID) with a stronger in 
vitro anti-myeloma effect compared with “older” IMIDs – 
thalidomide and lenalidomide [24]. It may induce 
apoptosis via caspase-8, inhibit angiogenesis and 
cytokine secretion, and impede the interactions 
between stroma and myeloma cells. Moreover, it down-
regulates tumor necrosis factor-. Pomalidomide has 
shown encouraging results with a single case series 
demonstrating efficacy against extramedullary MM [26] 
and a recent case report illustrating its efficacy in CNS 
MM [6]. Pre-clinical studies in rats have shown 
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pomalidomide penetrates the BBB, highlighting its 
potential for therapy against CNS disease (unpublished 
observations).  
Marizomib, is a natural -lactone compound 
obtained from the marine bacterium Salinospora 
tropica. This unique class of PI is non-peptidic; its -
lactone ring can irreversibly inhibit proteasomal 
activities in vitro and in vivo. NPI-0052 exhibited a 
prolonged pan-proteasome inhibitory effect in an 
animal model, with more than 70 % inhibition of all 
three protease activities after twice weekly dosing and 
rapid distribution to tumor tissue after administration. 
The apoptotic cascade activation by NPI-0052 is more 
dependent on extrinsic (caspase-8-mediated) apoptotic 
signaling, in contrast to bortezomib, which is dependent 
on both extrinsic and intrinsic (caspase-9) apoptotic 
pathways. This agent also has oral bioavailability. A 
phase I study of marizomib in relapsed/refractory MM 
revealed CNS toxicity with dysphasia and ataxia, 
suggesting entry through the BBB and therefore a 
potential therapeutic agent in CNS MM [28]. 
These new molecules that can have some effects in 
CNS-MM need to be tested in to prospective large 
clinical trials, set to recruit enough number of patients. 
In particular the International Myeloma Working Group 
(IMWG) should be active investigating biology, genetics 
and new strategies also in this rare form of myeloma. 
The fight to CNS myeloma can begin!  
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